Loading news article.

Newsbenzinga

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Aug 11, 2026, 10:30 ET · Published

Article summary

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

An excerpt from the original article.

Related companies

AXSMAXSMView stock

Repost

Comments —

Loading comments…